tiprankstipranks
Advertisement
Advertisement

FOLD Stock Latest News

Amicus Therapeutics (FOLD) Q1 Earnings Cheat Sheet
Pre-EarningsAmicus Therapeutics (FOLD) Q1 Earnings Cheat Sheet
1M ago
FOLD
Amicus Completes Merger, Ends Nasdaq Listing and Reporting
PremiumCompany Announcements
Amicus Completes Merger, Ends Nasdaq Listing and Reporting
1M ago
8K
FOLD
BioMarin completes acquisition of Amicus Therapeutics
PremiumThe Fly
BioMarin completes acquisition of Amicus Therapeutics
1M ago
BMRN
FOLD
BioMarin resumed with an Overweight at Morgan Stanley
PremiumThe Fly
BioMarin resumed with an Overweight at Morgan Stanley
1M ago
BMRN
FOLD
Amicus Gains Final Approval for BioMarin Acquisition Completion
PremiumCompany Announcements
Amicus Gains Final Approval for BioMarin Acquisition Completion
2M ago
8K
FOLD
BioMarin price target lowered to $85 from $97 at BofA
PremiumThe FlyBioMarin price target lowered to $85 from $97 at BofA
3M ago
BMRN
FOLD
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
Premium
Company Announcements
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
3M ago
8K
FOLD
BioMarin price target raised to $104 from $98 at Canaccord
Premium
The Fly
BioMarin price target raised to $104 from $98 at Canaccord
3M ago
BMRN
FOLD
BioMarin price target lowered to $86 from $106 at Guggenheim
PremiumThe Fly
BioMarin price target lowered to $86 from $106 at Guggenheim
3M ago
BMRN
FOLD
BioMarin price target lowered to $95 from $98 at Oppenheimer
PremiumThe Fly
BioMarin price target lowered to $95 from $98 at Oppenheimer
4M ago
BMRN
FOLD
Maintaining a Hold: Solid Execution at Amicus but Limited Upside Ahead of the BioMarin Acquisition
PremiumRatings
Maintaining a Hold: Solid Execution at Amicus but Limited Upside Ahead of the BioMarin Acquisition
4M ago
FOLD
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
PremiumCompany Announcements
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
4M ago
FOLD
Amicus reports Q4 EPS 10c, consensus 18c
PremiumThe FlyAmicus reports Q4 EPS 10c, consensus 18c
4M ago
FOLD
Amicus Therapeutics (FOLD) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Amicus Therapeutics (FOLD) Q4 Earnings Cheat Sheet
4M ago
FOLD
Amicus presents new long-term data for Galafold, Pombiliti+ Opfolda
Premium
The Fly
Amicus presents new long-term data for Galafold, Pombiliti+ Opfolda
4M ago
FOLD
Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating
PremiumRatings
Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating
4M ago
FOLD
Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
PremiumWeekend Updates
Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
5M ago
COR
CLNN
Amicus downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Amicus downgraded to Hold from Buy at Jefferies
5M ago
FOLD
BioMarin upgraded to Buy from Hold at Canaccord
PremiumThe Fly
BioMarin upgraded to Buy from Hold at Canaccord
5M ago
BMRN
FOLD
Amicus downgraded to Neutral from Buy at Guggenheim
PremiumThe FlyAmicus downgraded to Neutral from Buy at Guggenheim
5M ago
FOLD
Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
Premium
The Fly
Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
5M ago
KKR
NVO
Amicus Therapeutics: Acquisition Premium Caps Upside, Driving Neutral Stance at BioMarin’s $14.50 Offer Price
Premium
Ratings
Amicus Therapeutics: Acquisition Premium Caps Upside, Driving Neutral Stance at BioMarin’s $14.50 Offer Price
5M ago
FOLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >